{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:43:51Z","timestamp":1793853831921,"version":"4.6.1"},"reference-count":158,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.blre.2025.101306","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T18:03:57Z","timestamp":1748801037000},"page":"101306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Advances in the critical care management for patients with hematological malignancies"],"prefix":"10.1016","volume":"74","author":[{"given":"Elie","family":"Azoulay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Zafrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Nates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara","family":"Chean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Ferreyro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith E.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe R.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Puxty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naike","family":"Big\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Mariotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Valade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Boell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Puntillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Lafarge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schellongowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Canet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Demoule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"P\u00e8ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laveena","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Shimabukuro-Vornhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Staudinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kochanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Lemiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Darmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Martin-Loeches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.blre.2025.101306_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.blre.2025.101306_bb0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S2213-2600(18)30345-X","article-title":"Acute respiratory failure in immunocompromised adults","volume":"7","author":"Azoulay","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.blre.2025.101306_bb0015","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/ajh.23158","article-title":"Bleeding and thrombosis in acute promyelocytic leukemia","volume":"87","author":"Choudhry","year":"2012","journal-title":"Am J Hematol"},{"issue":"22","key":"10.1016\/j.blre.2025.101306_bb0020","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2012.47.2365","article-title":"Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en r\u00e9animation onco-h\u00e9matologique study","volume":"31","author":"Azoulay","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.blre.2025.101306_bb0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/ckj\/sfx059","article-title":"Renal recovery after severe acute kidney injury in critically ill myeloma patients: a retrospective study","volume":"11","author":"Joseph","year":"2018","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1016\/j.blre.2025.101306_bb0030","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00134-023-07287-2","article-title":"Venous thromboembolism in critically ill adult patients with hematologic malignancy: a population-based cohort study","volume":"50","author":"Carini","year":"2024","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.blre.2025.101306_bb0035","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438662","article-title":"Advancements and challenges in the treatment of AML","volume":"44","author":"Abaza","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101306_bb0040","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/blood-2023-182045","article-title":"Outcomes in chemotherapy-ineligible elderly patients with newly diagnosed acute myeloid leukemia treated with venetoclax plus azacitidine: a pooled analysis","volume":"142","author":"Venditti","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2025.101306_bb0045","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.3109\/10428194.2016.1142083","article-title":"Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia","volume":"57","author":"Mamez","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.blre.2025.101306_bb0050","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00277-023-05119-3","article-title":"Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis","volume":"102","author":"Cerrano","year":"2023","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.blre.2025.101306_bb0055","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.2019003124","article-title":"Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia","volume":"136","author":"Gebru","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2025.101306_bb0060","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s00134-021-06502-2","article-title":"Critical illness in patients with hematologic malignancy: a population-based cohort study","volume":"47","author":"Ferreyro","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.blre.2025.101306_bb0065","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00277-018-3496-1","article-title":"Intensive care unit admission in patients with T cell lymphomas: clinical features and outcome","volume":"98","author":"Dumas","year":"2019","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.blre.2025.101306_bb0070","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3109\/10428194.2015.1106537","article-title":"Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma","volume":"57","author":"Wohlfarth","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2025.101306_bb0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13613-022-00990-1","article-title":"Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy","volume":"12","author":"Abdel-Nabey","year":"2022","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.blre.2025.101306_bb0080","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjh.12415","article-title":"Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en R\u00e9animation Respiratoire et Onco-H\u00e9matologique","volume":"162","author":"Darmon","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101306_bb0085","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1164\/rccm.201712-2452OC","article-title":"A multivariable prediction model for pneumocystis jirovecii pneumonia in hematology patients with acute respiratory failure","volume":"198","author":"Azoulay","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.blre.2025.101306_bb0090","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.blre.2025.101306_bb0095","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","article-title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study","volume":"8","author":"Azoulay","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101306_bb0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcrc.2020.04.008","article-title":"The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: surveying intensive care unit practices in the management of CAR T-cell associated toxicities","volume":"58","author":"Gutierrez","year":"2020","journal-title":"J Crit Care"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0105","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.blre.2025.101306_bb0110","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00134-024-07349-z","article-title":"Long-term survival and functional outcomes of critically ill patients with hematologic malignancies: a Canadian multicenter prospective study","volume":"50","author":"Munshi","year":"2024","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.blre.2025.101306_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrc.2022.154077","article-title":"Characteristics and outcomes of autologous hematopoietic stem cell transplant recipients admitted to intensive care units: a multicenter study","volume":"71","author":"Nassar","year":"2022","journal-title":"J Crit Care"},{"issue":"7","key":"10.1016\/j.blre.2025.101306_bb0120","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.blre.2025.101306_bb0125","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2017.17924","article-title":"Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial","volume":"318","author":"Bridoux","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.blre.2025.101306_bb0130","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-bcma bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.blre.2025.101306_bb0135","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jcrc.2020.10.022","article-title":"Impact of early ICU admission for critically ill cancer patients: post-hoc analysis of a prospective multicenter multinational dataset","volume":"62","author":"Hourmant","year":"2021","journal-title":"J Crit Care"},{"key":"10.1016\/j.blre.2025.101306_bb0140","article-title":"Diagnosis and outcome of acute respiratory failure in immunocompromised patients after bronchoscopy","volume":"54","author":"Bauer","year":"2019","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.blre.2025.101306_bb0145","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1164\/rccm.201001-0018OC","article-title":"Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial","volume":"182","author":"Azoulay","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.blre.2025.101306_bb0150","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1164\/rccm.201804-0681OC","article-title":"Clinical significance of upper airway virus detection in critically ill hematology patients","volume":"199","author":"Legoff","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.blre.2025.101306_bb0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1164\/rccm.202009-3575OC","article-title":"Survival in immunocompromised patients ultimately requiring invasive mechanical ventilation: a pooled individual patient data analysis","volume":"204","author":"Dumas","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.blre.2025.101306_bb0160","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1038\/s41375-020-0783-3","article-title":"Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study","volume":"34","author":"Stahl","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2025.101306_bb0165","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1365-2141.1997.1943011.x","article-title":"Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate","volume":"98","author":"Porcu","year":"1997","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2025.101306_bb0170","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/trf.15994","article-title":"Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-a systematic review and meta-analysis","volume":"60","author":"Bewersdorf","year":"2020","journal-title":"Transfusion (Paris)"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0175","first-page":"141","article-title":"Comparison of early mortality between leukapheresis and non-leukapheresis in adult acute myeloid leukemia patients with hyperleukocytosis: a systematic review and meta-analysis","volume":"27","author":"Rinaldi","year":"2022","journal-title":"Hematol Amst Neth"},{"issue":"6","key":"10.1016\/j.blre.2025.101306_bb0180","first-page":"833","article-title":"Pulmonary Involvement in Leukemia","volume":"80","author":"Green","year":"1959","journal-title":"Am Rev Respir Dis"},{"issue":"19","key":"10.1016\/j.blre.2025.101306_bb0185","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJM195505122521903","article-title":"Manifestations of acute leukemia in the parenchyma of the lung","volume":"252","author":"Nathan","year":"1955","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2025.101306_bb0190","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2025.101306_bb0195","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1378\/chest.97.3.674","article-title":"Localized leukemic pulmonary infiltrates. Diagnosis by bronchoscopy and resolution with therapy","volume":"97","author":"Kovalski","year":"1990","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.blre.2025.101306_bb0200","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/1097-0142(19920315)69:6<1356::AID-CNCR2820690609>3.0.CO;2-B","article-title":"Acute lysis pneumopathy after chemotherapy for acute myelomonocytic leukemia with abnormal marrow eosinophils","volume":"69","author":"Dombret","year":"1992","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.blre.2025.101306_bb0205","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00134-023-07050-7","article-title":"ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med 2023","volume":"49","author":"Grasselli","year":"2023","journal-title":"Intensive Care Med"},{"issue":"5","key":"10.1016\/j.blre.2025.101306_bb0210","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.chest.2020.05.602","article-title":"Respiratory mechanics and outcomes in immunocompromised patients with ARDS: a secondary analysis of the EFRAIM study","volume":"158","author":"Demoule","year":"2020","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.blre.2025.101306_bb0215","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1007\/s00134-014-3354-0","article-title":"Acute respiratory distress syndrome in patients with malignancies","volume":"40","author":"Azoulay","year":"2014","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0220","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13613-024-01373-4","article-title":"Acute respiratory distress syndrome in patients with hematological malignancies: a one-year retrospective nationwide cohort study","volume":"14","author":"Bris","year":"2024","journal-title":"Ann Intensive Care"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0225","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13054-018-2079-9","article-title":"Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database","volume":"22","author":"Cortegiani","year":"2018","journal-title":"Crit Care Lond Engl"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0230","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13054-024-05073-0","article-title":"Septic shock in the immunocompromised cancer patient: a narrative review","volume":"28","author":"Nates","year":"2024","journal-title":"Crit Care Lond Engl"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0235","article-title":"Impact of multidrug resistance on outcomes in hematologic cancer patients with bacterial bloodstream infections","volume":"14","author":"Park","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.blre.2025.101306_bb0240","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/CCM.0B013E318165314B","article-title":"Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit","volume":"36","author":"P\u00e8ne","year":"2008","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0245","doi-asserted-by":"crossref","first-page":"45","DOI":"10.6004\/jnccn.2021.7046","article-title":"Outcomes and predictors of 28-day mortality in patients with hematologic malignancies and septic shock defined by sepsis-3 criteria","volume":"20","author":"Manjappachar","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"issue":"2","key":"10.1016\/j.blre.2025.101306_bb0250","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00134-014-3615-y","article-title":"Prognosis of neutropenic patients admitted to the intensive care unit","volume":"41","author":"Mokart","year":"2015","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.blre.2025.101306_bb0255","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/vox.12411","article-title":"Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial","volume":"111","author":"Hess","year":"2016","journal-title":"Vox Sang"},{"issue":"2","key":"10.1016\/j.blre.2025.101306_bb0260","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/trf.15596","article-title":"Post-transfusion platelet responses in critically ill cancer patients with hypoproliferative thrombocytopenia","volume":"60","author":"Baron","year":"2020","journal-title":"Transfusion (Paris)"},{"issue":"11","key":"10.1016\/j.blre.2025.101306_bb0265","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/blood.2022016308","article-title":"Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial","volume":"140","author":"Gernsheimer","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101306_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101135","article-title":"Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management","volume":"62","author":"Panch","year":"2023","journal-title":"Blood Rev"},{"issue":"12","key":"10.1016\/j.blre.2025.101306_bb0275","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1111\/jth.15074","article-title":"Management of hemostatic complications in acute leukemia: guidance from the SSC of the ISTH","volume":"18","author":"Wang","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.blre.2025.101306_bb0280","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00134-024-07454-z","article-title":"Management of hematological patients requiring emergency chemotherapy in the intensive care unit","volume":"50","author":"Lafarge","year":"2024","journal-title":"Intensive Care Med"},{"issue":"5","key":"10.1016\/j.blre.2025.101306_bb0285","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s12185-023-03690-z","article-title":"Cancer-associated thrombosis in hematologic malignancies","volume":"119","author":"Fukatsu","year":"2024","journal-title":"Int J Hematol"},{"issue":"11","key":"10.1016\/j.blre.2025.101306_bb0290","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/jth.14578","article-title":"Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation","volume":"17","author":"Iba","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.blre.2025.101306_bb0295","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1160\/TH15-09-0740","article-title":"Supportive management strategies for disseminated intravascular coagulation. An international consensus","volume":"115","author":"Squizzato","year":"2016","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.blre.2025.101306_bb0300","doi-asserted-by":"crossref","first-page":"e874","DOI":"10.1097\/CCM.0000000000005038","article-title":"Diagnostic performance of hemophagocytic lymphohistiocytosis criteria and HScore in critically ill patients with severe hemophagocytic syndrome","volume":"49","author":"Valade","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.blre.2025.101306_bb0305","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13613-022-01075-9","article-title":"Etoposide treatment in secondary hemophagocytic syndrome: impact on healthcare-associated infections and survival","volume":"12","author":"Dupont","year":"2022","journal-title":"Ann Intensive Care"},{"issue":"19","key":"10.1016\/j.blre.2025.101306_bb0310","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0315","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2016-02-700013","article-title":"Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice","volume":"128","author":"Maschalidi","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2025.101306_bb0320","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.blre.2025.101306_bb0325","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood-2018-06-846816","article-title":"Acute hyperviscosity: syndromes and management","volume":"132","author":"Gertz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101306_bb0330","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s00134-021-06521-z","article-title":"Preempting critical care services for patients with hematological malignancies","volume":"47","author":"Azoulay","year":"2021","journal-title":"Intensive Care Med"},{"issue":"9","key":"10.1016\/j.blre.2025.101306_bb0335","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00134-018-5347-x","article-title":"Improved short- and long-term outcome of allogeneic stem cell recipients admitted to the intensive care unit: a retrospective longitudinal analysis of 942 patients","volume":"44","author":"Lueck","year":"2018","journal-title":"Intensive Care Med"},{"issue":"8","key":"10.1016\/j.blre.2025.101306_bb0340","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1164\/rccm.202401-0135OC","article-title":"Outcomes in critically ill allogeneic hematopoietic stem-cell transplantation recipients","volume":"210","author":"Lafarge","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.blre.2025.101306_bb0345","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/s41409-020-0857-x","article-title":"Trajectories of acute graft-versus-host disease and mortality in critically ill allogeneic-hematopoietic stem cell recipients: the Allo-GRRR-OH score","volume":"55","author":"Pichereau","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.blre.2025.101306_bb0350","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00277-018-3320-y","article-title":"Allogeneic stem cell transplantation recipients requiring intensive care: time is of the essence","volume":"97","author":"Orvain","year":"2018","journal-title":"Ann Hematol"},{"issue":"20","key":"10.1016\/j.blre.2025.101306_bb0355","first-page":"2452","article-title":"How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy","volume":"141","author":"Gutierrez","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0360","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3322\/caac.21702","article-title":"Critical care management of chimeric antigen receptor T-cell therapy recipients","volume":"72","author":"Shimabukuro-Vornhagen","year":"2022","journal-title":"Cancer J Clin"},{"issue":"4","key":"10.1016\/j.blre.2025.101306_bb0365","first-page":"249","article-title":"Understanding, recognizing, and managing toxicities of targeted anticancer therapies","volume":"63","author":"Dy","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.blre.2025.101306_bb0370","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1\/2 study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.blre.2025.101306_bb0375","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.blre.2025.101306_bb0380","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/01.CCM.0000256846.27192.7A","article-title":"The ICU trial: a new admission policy for cancer patients requiring mechanical ventilation","volume":"35","author":"Lecuyer","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.blre.2025.101306_bb0385","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.2005.01.487","article-title":"Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study","volume":"23","author":"Thi\u00e9ry","year":"2005","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.blre.2025.101306_bb0390","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1200\/JCO.2016.66.9549","article-title":"Effects of organizational characteristics on outcomes and resource use in patients with cancer admitted to intensive care units","volume":"34","author":"Soares","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2025.101306_bb0395","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","article-title":"Delivering precision oncology to patients with cancer","volume":"28","author":"Mateo","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.blre.2025.101306_bb0400","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"3","key":"10.1016\/j.blre.2025.101306_bb0405","first-page":"264","article-title":"Interpreting and integrating genomic tests results in clinical cancer care: overview and practical guidance","volume":"74","author":"Casolino","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.blre.2025.101306_bb0410","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"issue":"15","key":"10.1016\/j.blre.2025.101306_bb0415","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJMoa1406617","article-title":"Lower versus higher hemoglobin threshold for transfusion in septic shock","volume":"371","author":"Holst","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2025.101306_bb0420","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM199902113400601","article-title":"A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group","volume":"340","author":"H\u00e9bert","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0425","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/ALN.0000000000000511","article-title":"Transfusion requirements in surgical oncology patients: a prospective, randomized controlled trial","volume":"122","author":"de Almeida","year":"2015","journal-title":"Anesthesiology"},{"issue":"5","key":"10.1016\/j.blre.2025.101306_bb0430","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/CCM.0000000000002283","article-title":"Liberal versus restrictive transfusion strategy in critically ill oncologic patients: the transfusion requirements in critically ill oncologic patients randomized controlled trial","volume":"45","author":"Bergamin","year":"2017","journal-title":"Crit Care Med"},{"issue":"13","key":"10.1016\/j.blre.2025.101306_bb0435","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1200\/JCO.19.01836","article-title":"Liberal versus restrictive red blood cell transfusion thresholds in hematopoietic cell transplantation: a randomized, open label, phase III, noninferiority trial","volume":"38","author":"Tay","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"19","key":"10.1016\/j.blre.2025.101306_bb0440","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1212772","article-title":"A no-prophylaxis platelet-transfusion strategy for hematologic cancers","volume":"368","author":"Stanworth","year":"2013","journal-title":"N Engl J Med"},{"issue":"9850","key":"10.1016\/j.blre.2025.101306_bb0445","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(12)60689-8","article-title":"Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study","volume":"380","author":"Wandt","year":"2012","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"10.1016\/j.blre.2025.101306_bb0450","article-title":"Different doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation","author":"Estcourt","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.blre.2025.101306_bb0455","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.14423","article-title":"Guidelines for the use of platelet transfusions","volume":"176","author":"Estcourt","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101306_bb0460","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00134-019-05653-7","article-title":"Changes in critically ill cancer patients short-term outcome over the last decades: results of systematic review with meta-analysis on individual data","volume":"45","author":"Darmon","year":"2019","journal-title":"Intensive Care Med"},{"issue":"6","key":"10.1016\/j.blre.2025.101306_bb0465","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.blre.2015.04.002","article-title":"Managing critically Ill hematology patients: Time to think differently","volume":"29","author":"Azoulay","year":"2015","journal-title":"Blood Rev"},{"issue":"7","key":"10.1016\/j.blre.2025.101306_bb0470","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s00134-019-05650-w","article-title":"Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases","volume":"45","author":"Assoun","year":"2019","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0475","doi-asserted-by":"crossref","first-page":"97.e1","DOI":"10.1016\/j.jtct.2023.10.010","article-title":"Severity of chronic graft-versus-host disease and late effects following allogeneic hematopoietic cell transplantation for adults with hematologic malignancy","volume":"30","author":"Lee","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2025.101306_bb0480","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1183\/09031936.00142907","article-title":"Case volume and mortality in haematological patients with acute respiratory failure","volume":"32","author":"Lecuyer","year":"2008","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.blre.2025.101306_bb0485","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s00134-017-4947-1","article-title":"Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care Med 2017","volume":"43","author":"Azoulay","year":"2017","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.blre.2025.101306_bb0490","doi-asserted-by":"crossref","DOI":"10.2196\/58503","article-title":"Clinicians\u2019 perspectives on the telehealth serious illness care program for older adults with myeloid malignancies: single-arm pilot study","volume":"8","author":"LoCastro","year":"2024","journal-title":"JMIR Form Res"},{"issue":"3","key":"10.1016\/j.blre.2025.101306_bb0495","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/cc3486","article-title":"Withdrawing may be preferable to withholding","volume":"9","author":"Vincent","year":"2005","journal-title":"Crit Care Lond Engl"},{"issue":"9","key":"10.1016\/j.blre.2025.101306_bb0500","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00134-018-5339-x","article-title":"Time-limited trial of intensive care treatment: an overview of current literature","volume":"44","author":"Vink","year":"2018","journal-title":"Intensive Care Med"},{"issue":"4","key":"10.1016\/j.blre.2025.101306_bb0505","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.chest.2023.12.014","article-title":"Time-limited trials for patients with critical illness: a review of the literature","volume":"165","author":"Kruser","year":"2024","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.blre.2025.101306_bb0510","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1513\/AnnalsATS.202310-925ST","article-title":"Defining the time-limited trial for patients with critical illness: an official american thoracic society workshop report","volume":"21","author":"Kruser","year":"2024","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0515","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jamaoncol.2015.3336","article-title":"Time-limited trials of intensive care for critically ill patients with cancer: how long is long enough?","volume":"2","author":"Shrime","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0520","first-page":"120","article-title":"\u201cHope at a crossroads\u201d - Experiences of hope in intensive care patients: a qualitative study","volume":"37","author":"Berntzen","year":"2024","journal-title":"Aust Crit Care Off J Confed Aust Crit Care Nurses"},{"issue":"26","key":"10.1016\/j.blre.2025.101306_bb0525","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMp1303295","article-title":"Uncertainty--the other side of prognosis","volume":"368","author":"Smith","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2025.101306_bb0530","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1097\/CCM.0000000000001270","article-title":"Acutely bereaved surrogates\u2019 stories about the decision to limit life support in the ICU","volume":"43","author":"Nunez","year":"2015","journal-title":"Crit Care Med"},{"issue":"5","key":"10.1016\/j.blre.2025.101306_bb0535","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s11606-023-08596-4","article-title":"Navigating uncertainty in clinical practice: a structured approach","volume":"39","author":"Patel","year":"2024","journal-title":"J Gen Intern Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0540","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jpainsymman.2019.04.028","article-title":"Giving voice to patient values throughout cancer: a novel nurse-led intervention","volume":"58","author":"Epstein","year":"2019","journal-title":"J Pain Symptom Manag"},{"issue":"31","key":"10.1016\/j.blre.2025.101306_bb0545","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2017.75.2311","article-title":"Patient-clinician communication: american society of clinical oncology consensus guideline","volume":"35","author":"Gilligan","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2025.101306_bb0550","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamaoncol.2024.5572","article-title":"A values proposition for cancer care. JAMA Oncol 2024","volume":"11","author":"Rosa","year":"2025","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101306_bb0555","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1089\/jpm.2022.0075","article-title":"The platinum rule: a new standard for person-centered care","volume":"25","author":"Chochinov","year":"2022","journal-title":"J Palliat Med"},{"issue":"6","key":"10.1016\/j.blre.2025.101306_bb0560","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jpainsymman.2014.11.291","article-title":"Eliciting personhood within clinical practice: effects on patients, families, and health care providers","volume":"49","author":"Chochinov","year":"2015","journal-title":"J Pain Symptom Manag"},{"issue":"24","key":"10.1016\/j.blre.2025.101306_bb0565","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1056\/NEJMp0906516","article-title":"The breadth of hopes","volume":"361","author":"Feudtner","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087779","article-title":"Long-term health related quality of life following intensive care during treatment for haematological malignancies","volume":"9","author":"van Vliet","year":"2014","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.blre.2025.101306_bb0575","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00003246-200102000-00010","article-title":"Self-reported symptom experience of critically ill cancer patients receiving intensive care","volume":"29","author":"Nelson","year":"2001","journal-title":"Crit Care Med"},{"issue":"11","key":"10.1016\/j.blre.2025.101306_bb0580","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1097\/CCM.0b013e3181f267ee","article-title":"Symptoms experienced by intensive care unit patients at high risk of dying","volume":"38","author":"Puntillo","year":"2010","journal-title":"Crit Care Med"},{"issue":"11","key":"10.1016\/j.blre.2025.101306_bb0585","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00134-023-07219-0","article-title":"Self-reported symptoms experienced by intensive care unit patients: a prospective observational multicenter study","volume":"49","author":"Saltnes-Lilleg\u00e5rd","year":"2023","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.blre.2025.101306_bb0590","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00134-023-07246-x","article-title":"Dyspnoea in acutely ill mechanically ventilated adult patients: an ERS\/ESICM statement","volume":"50","author":"Demoule","year":"2024","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.blre.2025.101306_bb0595","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00134-018-05511-y","article-title":"Tailored multicomponent program for discomfort reduction in critically ill patients may decrease post-traumatic stress disorder in general ICU survivors at 1 year","volume":"45","author":"Kalfon","year":"2019","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.blre.2025.101306_bb0600","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00134-013-3153-z","article-title":"Palliative care in the ICU: relief of pain, dyspnea, and thirst--a report from the IPAL-ICU Advisory Board","volume":"40","author":"Puntillo","year":"2014","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.blre.2025.101306_bb0605","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00134-019-05906-5","article-title":"Diagnosis of severe respiratory infections in immunocompromised patients","volume":"46","author":"Azoulay","year":"2020","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0610","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/CCM.0b013e31822b50c2","article-title":"Survival in neutropenic patients with severe sepsis or septic shock","volume":"40","author":"Legrand","year":"2012","journal-title":"Crit Care Med"},{"issue":"12","key":"10.1016\/j.blre.2025.101306_bb0615","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s00134-019-05789-6","article-title":"Invasive pulmonary aspergillosis in critically ill patients with hematological malignancies","volume":"45","author":"Pardo","year":"2019","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0620","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13613-021-00818-4","article-title":"Poor outcome associated with mucormycosis in critically ill hematological patients: results of a multicenter study","volume":"11","author":"Jestin","year":"2021","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.blre.2025.101306_bb0625","first-page":"237","article-title":"Invasive pneumococcal disease among adults with hematological and solid organ malignancies: a population-based cohort study","volume":"106","author":"Garcia Garrido","year":"2021","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0630","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00134-024-07737-5","article-title":"What intensivists need to know about cytomegalovirus infection in immunocompromised ICU patients. Intensive Care Med 2025","volume":"51","author":"Fern\u00e1ndez","year":"2025","journal-title":"Intensive Care Med"},{"issue":"5","key":"10.1016\/j.blre.2025.101306_bb0635","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0002-9343(86)90634-0","article-title":"Disseminated atypical mycobacterial infection in patients with hairy cell leukemia","volume":"80","author":"Bennett","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2025.101306_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100635","article-title":"Immunomodulatory effect of ibrutinib: reducing the barrier against fungal infections","volume":"40","author":"Maffei","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101306_bb0645","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13613-016-0189-6","volume":"6","author":"Schnell","year":"2016","journal-title":"Ann Intensive Care"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0650","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2025.101306_bb0655","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy","volume":"3","author":"Mariotte","year":"2016","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.blre.2025.101306_bb0660","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.blre.2025.101306_bb0665","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/SHK.0000000000001553","article-title":"Aminoglycosides in immunocompromised critically ill patients with bacterial pneumonia and septic shock: a post-hoc analysis of a prospective multicenter multinational cohort","volume":"54","author":"Lopez","year":"2020","journal-title":"Shock"},{"issue":"3","key":"10.1016\/j.blre.2025.101306_bb0670","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1086\/376637","article-title":"Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy","volume":"37","author":"Cometta","year":"2003","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.blre.2025.101306_bb0675","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00134-019-05554-9","article-title":"De-escalation of antimicrobial therapy in critically ill hematology patients: a prospective cohort study","volume":"45","author":"Schnell","year":"2019","journal-title":"Intensive Care Med"},{"issue":"12","key":"10.1016\/j.blre.2025.101306_bb0680","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0685","article-title":"Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer","volume":"1","author":"Stern","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.blre.2025.101306_bb0690","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease. Lancet Infect Dis 2024. S1473\u20133099(23), 00692\u20138","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.blre.2025.101306_bb0695","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"97","author":"Mellinghoff","year":"2018","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.blre.2025.101306_bb0700","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00134-014-3408-3","article-title":"Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010)","volume":"40","author":"Lortholary","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.blre.2025.101306_bb0705","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.blre.2025.101306_bb0710","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/mmy\/myaa036","article-title":"Interlaboratory evaluation of Mucorales PCR assays for testing serum specimens: a study by the fungal PCR Initiative and the Modimucor study group","volume":"59","author":"Rocchi","year":"2021","journal-title":"Med Mycol"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2025.101306_bb0715","first-page":"5","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2025.101306_bb0720","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1007\/s00277-003-0773-3","article-title":"Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","volume":"82","author":"Cornely","year":"2003","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0725","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00134-013-3148-9","article-title":"De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study","volume":"40","author":"Mokart","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.blre.2025.101306_bb0730","doi-asserted-by":"crossref","unstructured":"Kriegl L, Egger M, Boyer J, Hoenigl M, Krause R. New treatment options for critically important WHO fungal priority pathogens. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 2024;S1198-743X(24)00118\u20136.","DOI":"10.1016\/j.cmi.2024.03.006"},{"key":"10.1016\/j.blre.2025.101306_bb0735","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10096-020-04118-w","article-title":"Characteristics and outcome according to underlying disease in non-AIDS patients with acute respiratory failure due to pneumocystis pneumonia","volume":"40","author":"Burghi","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0740","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s13054-023-04608-1","article-title":"Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG","volume":"27","author":"Giacobbe","year":"2023","journal-title":"Crit Care Lond Engl"},{"issue":"9","key":"10.1016\/j.blre.2025.101306_bb0745","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1093\/jac\/dkw156","article-title":"ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Alanio","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.blre.2025.101306_bb0750","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00277-023-05542-6","article-title":"Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study","volume":"103","author":"Brusosa","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2025.101306_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrc.2024.154766","article-title":"Cytomegalovirus infection in intensive care unit patients with hematological malignancies: characteristics and clinical outcomes","volume":"82","author":"Baber","year":"2024","journal-title":"J Crit Care"},{"key":"10.1016\/j.blre.2025.101306_bb0760","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jcrc.2021.08.015","article-title":"Herpesviridae in critically ill hematology patients: HHV-6 is associated with worse clinical outcome","volume":"66","author":"Gonzalez","year":"2021","journal-title":"J Crit Care"},{"issue":"1","key":"10.1016\/j.blre.2025.101306_bb0765","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13054-024-05029-4","article-title":"Clinical characteristics and outcomes of immunocompromised critically ill patients with cytomegalovirus end-organ disease: a multicenter retrospective cohort study","volume":"28","author":"Fern\u00e1ndez","year":"2024","journal-title":"Crit Care Lond Engl"},{"issue":"11","key":"10.1016\/j.blre.2025.101306_bb0770","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3324\/haematol.2019.223073","article-title":"Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation","volume":"104","author":"Ward","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.blre.2025.101306_bb0775","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/tid.12022","article-title":"European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011)","volume":"14","author":"Matthes-Martin","year":"2012","journal-title":"Transpl Infect Dis Off J Transplant Soc"},{"issue":"5","key":"10.1016\/j.blre.2025.101306_bb0780","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00277-019-03622-0","article-title":"Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO)","volume":"98","author":"Kochanek","year":"2019","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.blre.2025.101306_bb0785","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181808","article-title":"Respiratory events in ward are associated with later intensive care unit (ICU) admission and hospital mortality in onco-hematology patients not admitted to ICU after a first request","volume":"12","author":"Doukhan","year":"2017","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.blre.2025.101306_bb0790","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2450","article-title":"Trends in adult cancer-related emergency department utilization: an analysis of data from the nationwide emergency department sample","volume":"3","author":"Rivera","year":"2017","journal-title":"JAMA Oncol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:31:46Z","timestamp":1766079106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":158,"alternative-id":["S0268960X25000517"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101306","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the critical care management for patients with hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101306"}}